Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782826 | 0.89 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRBTDP1CHRM1 | |
| SCHEMBL8330635 | 0.82 | ALDH1A1 (0.39) | ALDH1A1TSHRTHRBTDP1CA2 | |
| SCHEMBL9516593 | 0.81 | NOS3 (0.38) | ALDH1A1TSHRTDP1CHRM1AKR1A1 | |
| SCHEMBL7486384 | 0.81 | TDP1 (0.47) | ALDH1A1TSHRTHRBTDP1MAPK1 | |
| SCHEMBL566391 | 0.81 | GABRR1 (0.48) | ALDH1A1TSHRTHRBTDP1CHRM1 | |
| SCHEMBL8770290 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHRTHRBTDP1NOS3 | |
| SCHEMBL4853056 | 0.79 | NOS3 (0.56) | ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL4853049 | 0.79 | NOS3 (0.56) | ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL8000093 | 0.79 | RNPEP (0.47) | ALDH1A1TSHRTHRBTDP1CHRM1 | |
| SCHEMBL3820505 | 0.79 | CA2 (0.54) | ALDH1A1TSHRTHRBTDP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966466-B1 | PYRROLO 3,2-c]QUINOLINE DERIVATIVES CONTAINING HALOALKOXY GROUP AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KOREA RES INST CHEM TECH (KR) | 2002-07-03 | — | — | EP | claimed |
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1848721-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082401-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| US-4847377-A | ANTIHYPERPROLIFERATIVE SKIN DISEASES | SCHERING CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4816458-A | TOPICAL ADMINISTERING | SCHERING CORPORATION (US) | 1989-03-28 | — | — | US | disclosed |
| US-4569936-A | Anti-inflammatory substituted 9H-8-oxo-pyrimido[2,1-f]purine-2,4-diones | SCHERING CORPORATION (US) | 1986-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | ALDH1A1 604/4885TSHR 4591/4885THRB 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.